Bracco's VueJect Achieves FDA Clearance and Health Canada Authorization for Cardiology Imaging

Bracco's VueJect Achieves Significant Regulatory Success

In a landmark achievement for Bracco Imaging, VueJect® has garnered crucial 510(k) clearance from the U.S. Food and Drug Administration (FDA) and authorization from Health Canada. This significant development marks the first dedicated ultrasound contrast delivery system tailored to enhance cardiology imaging, reinforcing Bracco's commitment to advancing healthcare through innovative technology.

VueJect’s introduction into the North American markets comes as a pivotal component of Bracco's global strategy for commercialization. The system is designed to optimize workflow efficiency in cardiology imaging, standardizing the contrast administration process while simultaneously reducing operator variability. This ensures healthcare professionals can achieve consistent enhancement during cardiac imaging procedures, setting a new benchmark for excellence in diagnostics.

A Leap Forward in Cardiovascular Diagnostics

Bracco’s VueJect is more than just a technical advancement; it symbolizes the company’s strategic vision for the future of contrast-enhanced ultrasound (CEUS). According to Fulvio Renoldi Bracco, Vice Chairman and CEO, “VueJect signifies a crucial milestone for Bracco as we invest in innovations that enhance contrast-enhanced ultrasound globally.” This introduction is expected to yield significant benefits not only for healthcare providers but also for patients who rely on precise and timely diagnostics.

VueJect empowers cardiac sonographers by offering a user-friendly, standardized method for administering ultrasound contrast agents, specifically Lumason/SonoVue, in echocardiography procedures. This dedicated approach promises to enhance the overall quality of examinations conducted in cardiology, benefitting clinicians and patients alike.

Luca Frazzoli, Global Head of Ultrasound at Bracco Imaging, commented that VueJect brings a transformative approach to contrast administration. It is anticipated to elevate expectations for consistency and reliability within daily clinical practices, ultimately driving advancements in patient care.

Impact and Future Plans

The pathway to regulatory approval in the United States and Canada marks a major step in Bracco’s expansion plans. Following these milestones, the company is gearing up for a full commercial launch of VueJect while pursuing further regulatory submissions in global markets. As it stands, VueJect enhances Bracco's already robust CEUS ecosystem by introducing crucial innovations that facilitate better cardiac imaging results.

Robert Mitchell, Director of the Ultrasound Platform for the Americas, emphasized the significant ramifications of VueJect’s clearance: it offers clinicians a more consistent approach to contrast administration, which can directly impact the quality of CEUS examinations performed routinely.

As Bracco continues to champion advancements in diagnostic imaging, VueJect stands as a testament to their ongoing commitment to quality care. This technology not only revolutionizes how contrast is administered but also signifies Bracco’s dedication to providing innovative solutions that improve healthcare accessibility worldwide.

Bracco, a stalwart in diagnostic imaging since its inception in 1927, operates globally in over 100 countries, generating significant revenues primarily from international markets. With a commitment to innovation—investing approximately 9% of its annual sales into research and development—Bracco remains at the forefront of medical imaging advancements. Their continuous efforts are highlighted by their extensive portfolio of pharmaceutical products and advanced technologies for cardiovascular and radiological imaging.

For further information about Bracco Imaging and the innovative VueJect system, please visit www.bracco.com.

VueJect is a registered trademark of Bracco Imaging S.p.A.